Abstract
Introduction
Insulin-dependent diabetes mellitus (Type 1 diabetes, T1D) is due to the autoimmune destruction of insulin producing pancreatic islet beta cells by autoreactive effector T lymphocytes [1, 2] . Within its multifactorial pathogenesis, a close interaction of genetic background and environmental agents plays a major role. Establishment of thymic central tolerance in the perinatal age leads to elimination of autoreactive clones. Nevertheless, autoreactive T cells escape to thymic deletion and survive in the circulating peripheral blood (reviewed (rev) in [3, 2] ); this implies that the immune system homeostasis is also contributed by peripheral tolerance. Thus, both altered central and peripheral tolerance mechanisms affect the onset and progression of the clinical disease; in particular this implies an altered function of T regulatory cells (Tregs) that play a fundamental role in controlling host immunity to self-or non-self-proteins and infectious agents [2, 4] . To date the role of CD4 + CD25 + Tregs in controlling activation of effector autoreactive T lymphocytes in the pathogenesis of autoimmune disorders still requires to be fully elucidated [2, 5] . T1D studies in particular yielded conflicting results regarding their frequency and/or number as well as their suppressive function in T1D patients. Indeed, observed discrepancies across different investigations could be due to diverse biological materials employed such as lymphocytes obtained from the peripheral blood or lymph nodes, even from patients at different stage of disease (onset versus long-term) or of different ethnic populations [2] . We recently provided evidence for defects of CD4 + CD25 + CD127 low Tregs in the peripheral blood of T1D patients [2] . Their percentages were significantly higher in basal conditions while that of T effector cells (Teffs) significantly lower in patients than in controls. Tregs were functional in patients as Tregs ratio to Teffs was higher in patients than in controls. Further Treg subsets were characterized based on the expression of programmed-cell death (PD-1). PD-1 or CD279 and its ligand PDL-1 appear to play a significant effect on immune tolerance and cell death. Regarding PD-1/PDL-1 pathway, its regulation affects the function of several immunotypes including Tregs [2, 6] . In our study although percentages of total PD-1 + , PD-1 low and PD-1 high expressing Tregs were similar in patients and in controls in basal conditions, lower Tregs proliferation was observed upon anti-CD3/CD28 stimulation in diabetics [2] . Furthermore, percentages of total PD-1 + , PD-1 low and PD-1 high expressing Tregs subpopulations were lower in diabetics [2] . Recently, investigations aimed to identify and characterize other Tregs populations beside CD4 + CD25 + . In this regard, CD8 + T cells are recognized as adaptive immunological suppressive effectors in several conditions, i.e. cancer, transplantation, host defense and even autoimmune diseases (rev in [4] ). Authors have described also CD8 + Tregs, both in mice and humans [7] , that remained neglected for long time due to the lack of available unique markers [8] . Nevertheless, several subsets of CD8 + Tregs were depicted based on the expression of CD25, CD56 [9] , FoxP3, CXCR3, CD122, CD38, CD8αα, CD45RA, CD45RO, LAG-3 and/or HLA-G as well as the absence of CD28 expression and CD127 (rev in [10, 11] ). Several mechanisms are involved in CD8 + Tregs suppressive function: release of immunosuppressive factors and inhibitory cytokines such as IL-10 or direct lysis of target cells through cell-cell contact [12] . Furthermore, CD39 + CD26 -CD8 + Tregs release nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 containing extracellular vesicles that act by reducing phosphorylation of the T cell receptor (TCR)-associated kinase ZAP70 through reactive oxygen species (ROS) induction. Indeed, CD8 + Tregs were able to regulate general immune responses as well as specific autoimmune T cells keeping under control the normal T cell repertoire in the periphery [13] . Few evidences are reported so far for alterations of CD8 + suppressive T cells in human autoimmune diseases i.e. rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ankylosing spondylitis, systemic sclerosis, multiple sclerosis, myasthenia gravis, primary biliary cirrhosis, experimental autoimmune uveoretinitis, Hashimoto's thyroiditis and Graves' disease (rev in [14] ). Regarding T1D, suppressive CD8 + subsets were indeed able to prevent and even reverse T1D in non-obese diabetic (NOD) mice [15] where, in particular, the subset of CD8 + PD-1 + Tregs, expressing the β subunit of IL-2 receptor CD122 instead of CD25, revealed to be functional in ameliorating disease [16] . In a trial employing a modified anti-CD3 monoclonal antibody (mAb) [hOKT3γ1 (Ala-Ala)] in T1D patients, Bisikirska et al (2005) [17] originally depicted in responders an increased number and activation of CD8 + T cells upon treatment. In particular, anti-CD3 mAb induced the expansion of CD8
+ Tregs. This regulatory population was able to inhibit, through contact-dependent mechanism, CD4 + T cell responses to the mAb as well as to antigen [17] .
Complex interactions are postulated to occur between different subsets of Tregs in order to maintain a balance on the level of tolerance to self thus avoiding altered immunosuppression [18] . + cells arise spontaneously from non-pathogenic low-avidity clones and halt autoantigen-loaded antigen-presenting cells (APCs) in pancreatic lymph nodes [15] . In the light of the foregoing, the aim of this study was to evaluate percentages of CD8 + Tregs in the peripheral blood of T1D patients in different phases of disease at onset and during long-term disease in comparison with healthy subjects. Furthermore, we functionally assess these subsets based on the expression of PD-1 molecule.
Materials and methods

Subjects
The patient group consisted of 18 newly diagnosed (ND) and 13 long-standing (long-term, LT) T1D patients. To the ND group of patients belong those subjects recruited at the time of T1D diagnosis, while those subjects with at least 10 years of disease belong to the group of LT patients. Patients were recruited at the Department of Endocrinology at Bambino Gesù Children's Hospital (OPBG) over the past five years. Patients' sera were tested for diabetes-related autoantibodies (AAbs) i.e. glutamic acid decarboxylase isoform 65 (GADA), protein tyrosine phosphatase insulinoma-associated antigen 2 (IA2) and insulin (IAA) AAbs by radioimmunoassay (RIA), thyroglobulin (Tg), thyroperoxidase (TPO) and tissue transglutaminase (tTGA) AAbs by chemiluminescence (ADVIA Centaur analyzer: Siemens Healthcare, Germany), parietal cell (PCA), adrenal cortex (ACA) and islet cell AAbs by indirect immunofluorescence (IFL). Mean glycated hemoglobin (HbA1c) value of patients was 101.3 mmol/mol for newly diagnosed and 66.5 mmol/mol for long-term subjects (cut-off value 48 mmol/mol), indicating a poor metabolic control, which required insulin therapy adjustments. The control group of 20 HD, without family history for autoimmune diseases and no circulating AAbs, was recruited from the OPBG Blood Transfusion Division. All controls in respect to patients were matched for sex, age, ethnic and geographical origin. Enrolled individuals either patients or controls were unrelated. All subjects were recruited in the investigation after obtaining written informed consent. The study was approved by the local Institutional Review Board (IRB) of the OPBG, which regulates the use of human samples for experimental studies. The written informed consent for the children was obtained from the next of kin. The participants' consent was recorded using a paper-based inventory system. The IRB approved the consent procedure (1385_OPBG_2017, 14 June 2017).
Cell preparation
Peripheral blood mononuclear cells (PBMC) were separated by Ficoll-Hypaque (Histopaque, Sigma-Aldrich Chemical: St Louis, MO, USA) from sodium heparinized venous blood samples (5-10 mL). Samples were cryo-preserved in liquid-nitrogen according to standard procedures [2, 19] . 
Stimulation of PBMC with phorbol myristate (PMA)-ionomycin
Proliferation assay
In order to assess cell proliferation, before stimulation, PBMC were previously labeled with 0.1 μg/ml final concentration of 5-chloromethyl fluorescein diacetate (CMFDA) (CellTracker, Invitrogen, Molecular Probes, OR, USA) for 30 minutes at 37˚C, washed once by centrifugation at 1200 rpm for 5 minutes at RT and cultured at 7.5x10 5 cells per well in 96 well flat-bottom plates. Subsequently, the cells were stimulated as described above and incubated for three and five days at 37˚C in a humidified atmosphere containing 5% CO 2. Cell proliferation was assessed at three and five days by flow cytometry following the staining procedure described below.
Flow cytometry analysis (FACS)
In order to analyze untreated PBMC of HD, ND and LT patients under basal conditions, liquid-nitrogen frozen PBMC were thawed in complete RPMI medium and washed once by centrifugation at 1200 rpm for 5 minutes at RT. A total of 1. 
Correlation of main subsets analyzed and HbA1c
In evaluating the functional significance of divergences observed relative to the immune cell subsets under study in HD and T1D patients, a correlation analysis was performed to investigate the relation between the percentages of these subsets and relative HbA1c (mmol/mol) levels, which are indicative of the metabolic control, in both ND and LT T1D patients.
Statistical analysis
Due to unfeasibility of concurrent intracellular FoxP3 and CMFDA staining, out of the total group of T1D patients 9 ND and 10 LT were dedicated to the intracellular FoxP3 study while 9 ND and 9 LT were used for the CMFDA proliferation assay.
Differences among the various cell populations analyzed between healthy donors, newly diagnosed and long-term patients were tested for statistical significance with the One-way analysis of variance Kruskal-Wallis test and Dunn's Multiple Comparison post-test. The results were analyzed using GraphPad Prism software version number 5.00 (GraphPad Software: San Diego, CA, USA). A result with p < 0.05 was considered statistically significant. The correlation coefficients between percentages of subsets analyzed and metabolic parameter HbA1c was evaluated with Spearman test.
Results
Study population
Within the group of ND and LT T1D patients of the present investigation, the mean actual age of ND T1D patients was 10.8 years (ranging from 5 to 14 years; 11 males, 7 females). The mean age at disease onset was 7.7 years (ranging from 6 to 10 years). The mean actual age of LT T1D patients was 23.6 years (ranging from 20 to 30 years; 6 males, 7 females) and the mean duration of the disease was 13.8 years (ranging from 11 to 19 years). The mean age of the HD controls was 23 years (ranging from 18 to 30 years). Demographic and clinical characteristics of patients are shown in Table 1 and Table 2 . In addition to T1D (Table 1) , 1 newly diagnosed patient has developed autoimmune thyroid disease (AT). The same patient presented associated celiac disease (CD) and no other pathologies were found in the ND group of patients. Further, in addition to T1D (Table 2 ), 5 long-term patients have developed also AT (autoimmune polyglandular syndrome Type 3 variant, APS3v); of these 3 were affected by Hashimoto's thyroiditis (HT), confirmed by the presence of circulating Tg and TPO AAbs and echography pattern of diffuse hypoechogenicity, one patient had developed HT and vitiligo and one Basedow's disease. (Fig 5A-5C ), the proliferation of CD8 + cells (Fig 5A, Kruskal-Wallis one-way analysis of variance p = 0.0914) did not show significant differences between the groups of patients analyzed and the controls. However, the frequency of proliferating CD8 + Tregs (Fig 5B) appeared lower in both groups of T1D patients in respect to controls but it revealed to be significantly diminished especially in 
Analysis of CD8
Correlation between main analysed subsets and metabolic marker of disease HbA1c in patients
Analysis under basal conditions. No significant correlation was observed between percentages of CD8 + Treg cells (relative to Fig 1D) Analysis after PMA/ionomycin stimulation. After 3 days of PMA/ionomycin stimulation a significant inverse correlation was observed between percentages of CD8 + Treg cells and HbA1c levels in both ND (Fig 6A) and LT T1D patients (Fig 6B) . This suggests that low percentages of CD8 + Treg cells are indicative of a worse metabolic control. No significant correlation was found between HbA1c values and percentages of CD8 + Teff cells after 3 days of PMA/ ionomycin stimulation in ND (Fig 6C) and LT T1D patients (Fig 6D) . Regarding CD8 + Treg/ Teff cell ratio after stimulation, a significant correlation was not observed for ND (Fig 6E) while it was evident for LT T1D patients (Fig 6F) . Moreover, the study did not reveal a significant correlation between percentages of CD8 + Treg PD-1 + cells after stimulation and HbA1c levels in ND T1D patients (Fig 7A) while it showed a significant inverse correlation in LT T1D patients (Fig 7B) . Overall these data further suggest that low percentages of CD8 + Tregs and CD8 + Treg PD-1 + cells correlate with a worse metabolic control of disease in LT patients.
Discussion
Tregs are known to counteract autoreactive T cells and induce immune tolerance, through dampening inflammation. Regulatory mechanisms beyond their effects on T, B, natural killer (NK) and NKT cells are cell-to-cell-contact, secretion of immunosuppressive cytokines, effects on APCs, and competition for growth factors. In the light of the foregoing, novel immunotherapies could be exploited to target specifically Tregs in the perspective to avoid autoimmune disease onset and progression. For long time the only proposed treatment option was halting Teffs function, however, nowadays activating/ expanding Tregs is a novel avenue that may lead to improved outcomes with enhanced safety [21] (rev in [22] ).
In recent years, the complexity of natural and adaptive Tregs has therefore been the object of several studies [4, 23] sets. Regarding CD25, the question of Treg sensitivity to IL-2 is of upmost importance to fully unravel the utility and applicability of their robust suppressive activity in clinical settings [10, 22, [27] [28] . Tregs upon low-dose IL-2 treatment expressed enhanced levels of activation markers, including CD25, GITR, CTLA4 and basal phosphorylation of STAT5 (pSTAT5).
Tregs retained a 20-fold higher sensitivity to IL-2 than T effector and NK cells [22] . Interestingly CD8 + Tregs were more prone to expand to low IL-2 dose treatment than CD4 + Tregs [10] . In addition subsets were identified as CD8 , and effects on Teffs function has been intensively investigated by several authors in T1D patients (rev in [2, 37] ). We observed defects of the CD4 + population activation in longterm patients due to a lower expression of PD-1 on their surface. In this manuscript, no significant differences were depicted in the relative percentages of As conclusive remark, our pilot study identifies a novel CD8 + Treg cell population, which is defective in diabetics due to a lower expression of PD-1 on its surface. As also applied to other subsets of Tregs the characterization of the CD8 + Treg population in the pancreas and peripheral lymphnodes of T1D patient should be also elucidated, although we can foresee the limitation of the lack of human biological specimens. Furthermore, a future research avenue could be to test their 'antigen-specificity' since these have been reported as more potent in suppressing autoimmunity than polyclonal Tregs [37] . Definitively our results encourage further studies on the role of PD-1/PD-L1 pathway in controlling the autoimmune process in T1D patients for tailored immunotherapeutic approaches to be developed in years to come. 
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